Collectively, these in vitro preclinical PCa models represent common clinically relevant AR statuses and our data lead us to speculate that a PTGES3 inhibitor could inhibit AR function in diverse high-risk AR-driven mCRPC clinical scenarios. This evidence concerns the gene AR and posterior cortical atrophy.